Physician profile
Miriam Halazon
NPI 1568878023
$5,096.80
in general payments reported to CMS, 2019-2025
22 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,043 · 2022: $1,484 · 2023: $1,025 · 2024: $428 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.07 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $736.46 | 2021 | |
| Pfizer INC. | $581.59 | 2021-2025 | |
| Impulse Dynamics (USA) INC. | $373.96 | 2022-2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $368.60 | 2021-2025 | Amvuttra, Onpattro |
| Cvrx, INC. | $358.73 | 2023-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $352.81 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $288.00 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $278.69 | 2021-2025 | Wainua, Farxiga, Lokelma |
| Actelion Pharmaceuticals US, INC. | $251.88 | 2021-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.92 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $230.36 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $200.47 | 2023-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $172.38 | 2022-2025 | |
| Amgen INC. | $154.65 | 2022-2025 | Repatha, Repatha |
| Bridgebio Pharma, INC. | $124.31 | 2025 | Attruby |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $112.84 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $73.86 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $70.30 | 2022-2025 | Nexletol |
| Novo Nordisk INC | $51.21 | 2022-2025 | Wegovy |
| Edwards Lifesciences Corporation | $31.08 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Scpharmaceuticals INC. | $28.38 | 2025 | |
| Abiomed | $20.32 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriam Halazon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.